News

MedPage Today2h
A Peek at the Pipeline of Transcatheter Tricuspid Valve Replacement Systems
Progress with transcatheter tricuspid valve replacement (TTVR) candidate devices Topaz, LuX-Valve Plus, VDyne, and Trisol for ...
The Globe and Mail5d
Legend Biotech Announces New Oncologic & Hematologic Therapeutic Developments at ASCO, EHA, and ASGCT
SOMERSET, N.J., May 22, 2025 (GLOBE NEWSWIRE ... will be presented at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting and the 2025 European Hematology Association ...
manilatimes4d
Legend Biotech Announces New Oncologic & Hematologic Therapeutic Developments at ASCO, EHA, and ASGCT
SOMERSET, N.J., May 22, 2025 (GLOBE NEWSWIRE) -- Legend Biotech Corporation (NASDAQ ... myeloma will be presented at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting and the 2025 ...
Morningstar4d
IMUNON Announces 2025 ASCO Annual Meeting Oral Presentation Highlighting Unprecedented Survival Data from Phase 2 Trial of IMNN-001 in Treatment of Newly Diagnosed Advanced ...
“We are very encouraged by these remarkable results and the fact that they are being presented in two of the most prestigious platforms in oncology research – the ASCO Annual Meeting and ...
manilatimes4d
Biodesix Announces New Data on the VeriStrat® Test to be Presented at the 2025 ASCO Annual Meeting
May 22, 2025 (GLOBE NEWSWIRE) -- Biodesix, Inc. (Nasdaq: BDSX), a leading diagnostic solutions company, announced today that new data will be presented at the 2025 American Society of Clinical ...
Morningstar6d
Immix Biopharma to Host KOL Event to Discuss NXC-201 Clinical Data Presented at ASCO 2025 in relapsed/refractory AL Amyloidosis
LOS ANGELES, CA, May 21, 2025 (GLOBE NEWSWIRE ... following its 2025 American Society of Clinical Oncology (ASCO) Oral Presentation in Chicago, IL. The virtual KOL event will take place ...
The Globe and Mail4d
Oncolytics Biotech® to Present New Clinical Trial Data at ASCO Showing Pelareorep's Unique Immune Activation Capabilities
today announced new data from the Phase I/II GOBLET clinical trial in a poster presentation at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting. The presentation highlights ...
Joplin Globe15d
Circle Pharma to Present Trials in Progress Poster on CID-078, a First-in-Class Cyclin A/B Inhibitor, at the ASCO 2025 Annual Meeting
today announced that its Trials in Progress abstract has been selected for poster presentation at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting taking place May 30 to June 3 ...
Joplin Globe21d
Origin Specialty Insurance Transforms Claims Function With Origami Risk’s P&C Insurance Core Solution
Origin Specialty Underwriters Agency, LLC (“Origin Specialty”), an expansive Managing General Underwriter (“MGU”) leader in innovative risk solutions and partner company of Beyond Risk ...
WATE 6 On Your Side26d
18 presentations across five cancer types include new insights on the potential of checkpoint inhibitors and bispecific antibodies
TARRYTOWN, N.Y., May 01, 2025 (GLOBE NEWSWIRE ... will be shared at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting, taking place from May 30 to June 3 in Chicago, IL.
NBC4 Columbus5d
Transgene to Present 24-month Disease-Free Survival Data from All Patients in Phase I Part of Trial of Individualized Cancer Vaccine, TG4050, at ASCO 2025
The data will be shared during a rapid oral presentation at the American Society of Clinical Oncology (ASCO) Annual Meeting, taking place in Chicago from May 30 to June 3, 2025. TG4050 is a viral ...